-
- 抗原 See all C-Peptide ELISA试剂盒
- C-Peptide
-
适用
- 人
- 检测方法
- Colorimetric
- 实验类型
- Competition ELISA
- 应用范围
- ELISA
- 原理
- The C-Peptide Elisa Kit is based on the competition principle and the microplate separation. An unknown amount of C-Peptide present in the sample and a fixed amount of C-Peptide Conjugate compete for the binding sites of a polyclonal C-Peptide antiserum coated onto the wells. In a second step an Enzyme Complex binds to C-Peptide Conjugate. The unbound Enzyme Complex is washed off. Having added the Substrate Solution, the concentration of C-Peptide in the samples is inversely proportional to the optical density measured.
- Analytical Method
- Quantitative
- Featured
- Discover our best selling C-Peptide ELISA Kit
- Top Product
- Discover our top product C-Peptide ELISA Kit
-
-
- 板类型
- Pre-coated
- 限制
- 仅限研究用
-
- 储存条件
- 4 °C
-
-
Plasma phospholipids, non-esterified plasma polyunsaturated fatty acids and oxylipids are associated with BMI." in: Prostaglandins, leukotrienes, and essential fatty acids, Vol. 95, pp. 31-40, (2015) (PubMed).
: "Adaptive human CDKAL1 variants underlie hormonal response variations at the enteroinsular axis." in: PLoS ONE, Vol. 9, Issue 9, pp. e105410, (2014) (PubMed).
: "Cross-sectional analysis of obesity and serum analytes in males identifies sRAGE as a novel biomarker inversely associated with diverticulosis." in: PLoS ONE, Vol. 9, Issue 4, pp. e95232, (2014) (PubMed).
: "
-
Plasma phospholipids, non-esterified plasma polyunsaturated fatty acids and oxylipids are associated with BMI." in: Prostaglandins, leukotrienes, and essential fatty acids, Vol. 95, pp. 31-40, (2015) (PubMed).
-
- 抗原 See all C-Peptide ELISA试剂盒
- C-Peptide
- Abstract
- C-Peptide 产品
- 别名
- insulin 2 ELISA Kit, Ins2 ELISA Kit
- 背景
- Human C-Peptide has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin.The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin. C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests.C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
-